CD47 and cancer: It is also reasonable to speculate that the combination of KRAS inhibitors and immune checkpoint inhibitors, including inhibitors of PD-1/PD-L1 or CD47/SIRPα, could provide synergistic benefits to patients with KRAS-driven cancers.